Dynavax appoints chief medical officer
This article was originally published in Scrip
Executive Summary
Dynavax, a clinical-stage biopharmaceutical company developing products to treat infectious and inflammatory diseases, has appointed Dr Robert Janssen chief medical officer. Prior to joining Berkeley, California-based Dynavax, Dr Janssen was vice-president of medical affairs at Gilead. He also spent 23 years at the US Centers for Disease Control and Prevention (CDC), most recently as the director of the Division of HIV/AIDS Prevention.
You may also be interested in...
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.
In Vivo’s 2024 Rising Leaders
The fifth annual listing of In Vivo’s Rising Leaders includes entrepreneurs and innovators from across the world who represent the next wave of creativity in health care.